# Robert G. Maki

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-g-maki/

## Facts

| Field | Value |
| --- | --- |
| Citations | 53,621 |
| Field | Sarcoma Diagnosis and Treatment |
| h-index | 108 |
| i10-index | 311 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5068677359 |
| ORCID iD | https://orcid.org/0000-0002-9853-2528 |
| Works | 763 |

## Researcher papers

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-advanced-soft-tissue-sarcoma-and-bone-sarcoma-sarc028-a/)
- [NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors](https://scholariq.org/papers/nccn-task-force-report-update-on-the-management-of-patients-with/)
- [Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis](https://scholariq.org/papers/effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small/)
- [Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial](https://scholariq.org/papers/efficacy-and-safety-of-trabectedin-or-dacarbazine-for-metastatic-liposarcoma-or/)
- [Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002](https://scholariq.org/papers/randomized-phase-ii-study-of-gemcitabine-and-docetaxel-compared-with-gemcitabine/)
- [Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial](https://scholariq.org/papers/gemcitabine-and-docetaxel-in-patients-with-unresectable-leiomyosarcoma-results/)
- [Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas](https://scholariq.org/papers/phase-ii-study-of-sorafenib-in-patients-with-metastatic-or-recurrent-sarcomas/)
- [Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma](https://scholariq.org/papers/clinical-genomic-profiling-in-the-management-of-patients-with-soft-tissue-and/)

## Researcher topics

- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Gastrointestinal Tumor Research and Treatment](https://scholariq.org/topics/gastrointestinal-tumor-research-and-treatment/)
- [Vascular Tumors and Angiosarcomas](https://scholariq.org/topics/vascular-tumors-and-angiosarcomas-2/)
- [Cardiac tumors and thrombi](https://scholariq.org/topics/cardiac-tumors-and-thrombi/)
- [Soft tissue tumor case studies](https://scholariq.org/topics/soft-tissue-tumor-case-studies/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.